2021 ASCO Virtual Scientific Meeting

Visit HTG's customer posters presented at the 2021 ASCO Virtual Scientific Meeting? 

Abstract 506

Loibl, S., et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNuevo study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). 

Abstract 518

Marmé, F., et al.  Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B. 

Abstract 519

Denkert, C., et al. Subgroup of post-neoadjuvant luminal-Btumors assessed by HTG in PENELOPE-B investigating: First results from PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.

Abstract 558

Lopez-Guerrero, J. A., et al. MamaPred: a new and innovative approach to determine recurrence risk classification in luminal early-stage breast cancer using HTG EdgeSeq Technology

Abstract e14528 

Jaramillo, M. C., et al. Gene expression profiling signatures for immunophenotyping of tumor microenvironment using HTG EdgeSeq Precision Immuno-Oncology Panel.